transdermal glutathione | Stone Oak Womens Center Auro Wellness

Human trials are needed to confirm its safety and effectiveness before widespread clinical use

ChEMBL v34 compound record for TIRZEPATIDE (CHEMBL4297839): max_phase 4 (approved), first_approval 2022, parenteral, GIP receptor agonist, first-in-class, black-box warning flag

In summary, you can generally continue your other medications while on NAD+ injections, but keep your medical team informed and always follow their advice if they prefer to adjust dosing schedules or monitor certain lab parameters

Certain groups are at higher risk, including older adults (due to reduced stomach acid production), individuals with pernicious anaemia (an autoimmune condition affecting B12 absorption), those who have undergone gastrointestinal surgery, and people with conditions such as Crohn's disease or coeliac disease